Short communication · 8 Aug 2022
Conference abstractPublished 23 Sep 2013
The need for a reference product database for biosimilars
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The current draft guidance from the FDA, "Scientific Considerations in Demonstrating Biosimilarity to a Reference Product" provides guidance for the burden of proof necessary to obtain a biosimilar approval via section 351(k). The draft guidance recommends that a sponsor apply a stepwise approach, which will not necessarily be the same for all products. Furthermore, the draft guidance recommends "... the stepwise approach should start with extensive structural and functional characterization of both the proposed product and the reference product, which serves as the foundation of the biosimilar development program." It is also recommended that multiple manufacturing lots from multiple locations be analyzed and compared for the proposed and reference products. Accordingly, a reference product will have extensive structural characterization performed multiple times in a single biosimilar development program. Additionally, it is reasonably expected that multiple development programs will exist (from different companies) for a given reference compound. As a result, the reference compound will have been extensively analyzed many times over. A reference product database, consisting of structural and functional data for approved products, would enable biosimilar programs to realize significant reductions in total research effort and overall development expenditures. The impact would be faster times to market, lower costs, more competition, and ultimately lower costs to consumers and payers. Based on the above premise, a reference product database clearly seems logical. This begs the question, why does a universal yardstick for reference compounds not exist today? This presentation will explore the challenges to building an industry-wide database, how it could be developed, what data points should be included, and finally, stakeholders and their interests.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Oct 2018
Comparison between erythropoietin alfa biosimilars and reference product in anemic patients of chronic kidney disease
Review article · 2018
Biosimilars: A Review of Published Randomized Control Trials Comparing Biosimilars with their Reference Products
Conference abstract · 22 Jun 2017
Comparative repeated toxicity study in rats: Enoxaparin biosimilar product versus reference product
Conference abstract · 2018
Introducing biosimilar therapeutic products in oncology: The critical need for nurse education
More from this journal
The newest in Journal of Bioanalysis & Biomedicine.
Article · 29 Dec 2025
Label-Free Biosensing: Revolutionizing Disease Detection and Drug Discovery
Article · 29 Dec 2025
Epigenetic Modifications: Bioanalysis for Disease and Therapeutics
Article · 29 Dec 2025
Advancing Bioanalysis: New Tech, AI, and Precision Medicine
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Bioanalysis & Biomedicine
- BylineArticles whose byline prints “Jeff Lyons”

